| Amlodipine/Valsartan Single-Pill Combination: A Prospective, Observational Evaluation of the Real-Life Safety and Effectiveness in the Routine Treatment of Hypertension. | |
| | |
MedLine Citation:
|
PMID: 22271158 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
INTRODUCTION: As several international guidelines on hypertension have now recommended, singlepill/fixed-dose combination antihypertensive therapies may be particularly beneficial as firstline therapy in high-risk patients, in whom more rapid and pronounced blood pressure (BP) control is desired. Upon the single-pill combination of amlodipine and valsartan becoming available, the authors conducted this international, observational study to evaluate its efficacy and safety in a real-life practice setting. METHODS: This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily. Patients were observed over a 3-month period (12 weeks) with approximately monthly intervals between clinic visits. RESULTS: A total of 8336 patients completed all study visits and were included in the efficacy analysis. Mean age was 54.7 years and 83.4% of patients had received prior antihypertensive therapy. BP reductions were dose related. Overall, mean BP was reduced from 165.0/99.3 mmHg at baseline to 128.7/80.4 mmHg at 12 weeks (36.3/18.9 mmHg; P<0.0001). The magnitude of BP reduction rose with increasing severity of baseline BP. Control of BP (<140/90 mmHg) was achieved in 77.7% of patients. Efficacy was consistent in subgroups of patients with comorbidities and regardless of whether patients were previously treated with monotherapy or combination therapy. Adverse events were reported in 5.3% of patients. The incidence of edema declined from 10.4% at baseline to 8.5% at study end. CONCLUSION: Single-pill combination amlodipine/valsartan safely and effectively reduced BP across all hypertension grades and allowed the vast majority of patients to achieve BP goals. |
| | |
Authors:
|
Yuri Karpov; Neelesh Dongre; Alexey Vigdorchik; Krisada Sastravaha |
Related Documents
:
|
22235818 - Refractory hypertension: definition, prevalence, and patient characteristics. 21701398 - Physical fitness and perceived psychological pressure at work: 30-year ischemic heart d... 21805568 - Assessment of macro- and microcirculation in contemporary critical limb ischemia. 14756678 - An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volu... 7061128 - Carotid sinus baroreceptor control of arterial pressure in renovascular hypertensive su... 14974578 - Effects of extracorporeal shock wave therapy and radial pressure wave therapy on elasti... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-20 |
Journal Detail:
|
Title: Advances in therapy Volume: - ISSN: 1865-8652 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Russian Cardiology Scientific-Industrial Complex, Moscow, Russia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus.
Next Document: Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or ...